Pharmaceutical

Enterome to advance EO2463 immunotherapy with $19m funding

Enterome has secured $19m in new private funding to progress its EO2463 OncoMimics immunotherapy, targeting iNHL.

Jun 13, 2025 - 06:00
Enterome to advance EO2463 immunotherapy with $19m funding
Enterome has secured $19m in new private funding to progress its EO2463 OncoMimics immunotherapy, targeting iNHL.
Read the original article

Tags:

Previous Article

Vutrisiran marks first silencer approved for ATTR-CM

Next Article

Customs simplified: the need to streamline pharma shipments

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Key senators make a big pivot on bipartisan insulin cost proposal

Key senators make a big pivot on bipartisan insulin cos...

Apr 21, 2023

Marburg fever outbreak in Equatorial Guinea widens, WHO reports

Marburg fever outbreak in Equatorial Guinea widens, WHO...

Mar 22, 2023

The need to know biotech news stories today

The need to know biotech news stories today

Feb 13, 2024